Table 1.
Growth inhibitory activities of three actinomycins and Adriamycin in different cell lines.
| Compounds IC50 (nmol/L) |
MCF-7 | MDA-MB-231 | BT474 | MCF-10A | HMLE |
|---|---|---|---|---|---|
| Actinomycin V | 1.92 ± 0.25 | 0.83 ± 0.32 | 4.16 ± 0.25 | 4.07 ± 0.26 | 3.49 ± 0.31 |
| Actinomycin D | 8.23 ± 0.50 | 15.15 ± 0.52 | 37.00 ± 3.15 | 34.01 ± 0.25 | 30.22 ± 0.50 |
| Actinomycin Xob | 149.40 ± 4.03 | 127.33 ± 4.49 | 369.90 ± 0.14 | 248.57 ± 14.69 | 105.83 ± 8.44 |
| Adriamycin | 885.38 ± 13.50 | 942.60 ± 22.50 | 584.70 ± 50.00 | 1489.13 ± 25.50 | 1627 ± 15.50 |
1 The effects of three actinomycins and Adriamycin on various human breast cancer cells (MCF-7, MDA-MB-231, and BT474) and normal human breast epithelial cell lines (HMLE and MCF-10A) were examined by 3-(4,5-Dimethylthiazol)-2,5-diphenyltetrazolium bromide (MTT) assay. The cells were treated with various concentrations of compounds for 48 h and the IC50 values were then calculated. Results were obtained from three independent experiments. Data were expressed as the mean ± SD (Standard Deviation) of triplicate experiments.